3,4-Diaminopyridine in the Treatment of Lambert–Eaton Myasthenic Syndrome
- 7 December 1989
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 321 (23) , 1567-1571
- https://doi.org/10.1056/nejm198912073212303
Abstract
Lambert–Eaton myasthenic syndrome is characterized by muscle weakness, hyporeflexia, and autonomic dysfunction, which result from impaired release of acetylcholine from cholinergic nerve terminals. It is frequently associated with cancer, it is autoimmune-mediated, and treatment has been unsatisfactory.This publication has 22 references indexed in Scilit:
- Calcium ions, active zones and synaptic transmitter releaseTrends in Neurosciences, 1988
- Isometric Elbow Strength in Normal IndividualsPublished by Wolters Kluwer Health ,1987
- Lambert‐Eaton Myasthenic Syndrome IgG: Early Morphologic Effects and Immunolocalization at the Motor EndplateaAnnals of the New York Academy of Sciences, 1987
- Action of Lambert‐Eaton myasthenic syndrome IgG at mouse motor nerve terminalsAnnals of Neurology, 1985
- Proceedings of the meeting of the Association of British Neurologists held jointly with the Polish Neurological Society in London, April 1984Journal of Neurology, Neurosurgery & Psychiatry, 1984
- Functional evaluation of total knee replacementJournal of Orthopaedic Research, 1984
- Quantitative sudomotor axon reflex test in normal and neuropathic subjectsAnnals of Neurology, 1983
- AUTOIMMUNE AETIOLOGY FOR MYASTHENIC (EATON-LAMBERT) SYNDROMEThe Lancet, 1981
- Estimates of quantal content during 'chemical potentiation' of transmitter releaseProceedings of the Royal Society of London. B. Biological Sciences, 1979
- DEFECTS OF NEUROMUSCULAR TRANSMISSION IN SYNDROMES OTHER THAN MYASTHENIA GRAVISAnnals of the New York Academy of Sciences, 1966